Carbon Biosciences is focused on advancing genetic medicines to treat challenging diseases by leveraging the natural evolution of viruses. The company utilizes a proprietary CBN vector library, which offers significant advantages such as enhanced tissue specificity, the ability to carry larger genetic payloads, and the potential for long-lasting treatment effects. This innovative approach aims to overcome the limitations of traditional gene therapy methods, particularly in targeting diseases like cystic fibrosis. By combining the genetic diversity of evolved viruses with modern clinical and manufacturing advancements, Carbon Biosciences seeks to unlock the full potential of gene therapy.

The company's strategy emphasizes the importance of utilizing engineered viral vectors that have been validated by nature, thereby reducing risks associated with gene therapy. Carbon Biosciences aims to harness the power of these natural viral mechanisms to deliver effective treatments across various modalities. Their commitment to developing next-generation gene therapies is underscored by significant financial backing and a dedicated team of experts in drug development, ensuring a robust pipeline of innovative therapeutic solutions.

United States

Carbon Biosciences is a team of passionate drug developers extending the reach of genetic medicines for the treatment of devastating diseases. We combine the genetic diversity and potency of viruses that have evolved over millions of years with the recent clinical and manufacturing advances in the gene therapy field. Our proprietary CBN vector library has the potential advantages of exquisite tissue specificity, larger payloads and durable treatment strategies across multiple modalities. Our goal: realize the power of natural viral evolution and deliver on the promise of genetic medicines.

Carbon Biosciences

Company Details